Evidence map›Paper›PMID 39161369›Full record

ArticleCase reports in immunology2024

Two Unrelated Iranian Patients with Adenosine Deaminase 2 Deficiency: A Case Report and Review of Treatment.

Parvaneh Karimzade, Aziz Eghbali, Mohammad Keramatipour, Reza Shiari, Zahra Golchehre, Mahdieh Taghizadeh, Mazdak Fallahi, Shahrzad Fallah, Nasrin Khakbazan Fard, Narges Eslami and 3 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Parvaneh KarimzadePediatric Neurology Research Center Research Institute for Children's Health Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Aziz EghbaliDepartment of Pediatrics School of Medicine Iran University of Medical Sciences, Tehran, Iran.
Mohammad KeramatipourDepartment of Medical Genetics School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
Reza ShiariDivision of Pediatric Rheumatology Department of Pediatrics Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zahra GolchehreDepartment of Medical Genetics School of Medicine Tehran University of Medical Sciences, Tehran, Iran.
Mahdieh TaghizadehWatson Genetic Laboratory, North Kargar Street, Tehran, Iran.
Mazdak FallahiImmunology and Allergy Department Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shahrzad FallahImmunology and Allergy Department Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nasrin Khakbazan FardImmunology and Allergy Department Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Narges EslamiImmunology and Allergy Department Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Narges BazgirHearing Disorders Research Center Loghman Hakim Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-6443-9448
Mahnaz JameeImmunology and Allergy Department Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0002-0732-9170
Zahra ChavoshzadehImmunology and Allergy Department Mofid Children's Hospital Shahid Beheshti University of Medical Sciences, Tehran, Iran.ORCID https://orcid.org/0000-0003-1869-8630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adenosine deaminase deficiency 2 (DADA2) is an autoinflammatory disorder, caused by the Conclusion: In this case report, we discussed two cases with DADA2 deficiency and their respective manifestations. The first case showed neurological symptoms while the second case had hematological symptoms. Although there is no established treatment for DADA2 due to its rarity, steroids are commonly used to treat this disorder. Antitumor necrosis factor is also effective in controlling the symptoms, especially the neurological ones. In cases where there is no appropriate response to these treatments, hematopoietic stem cell transplantation can be beneficial.

Identifiers

PMID39161369
PMCPMC11333127

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.